Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
Top Cited Papers
- 18 February 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (3) , 172-183
- https://doi.org/10.1038/nrc1567
Abstract
Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR-ABL, has shown remarkable clinical activity in patients with chronic myelogenous leukaemia (CML). However, this drug does not completely eradicate BCR-ABL-expressing cells from the body, and resistance to imatinib emerges. Although BCR-ABL remains an attractive therapeutic target, it is important to identify other components involved in CML pathogenesis to overcome this resistance. What have clinical trials of imatinib and studies using mouse models for BCR-ABL leukaemogenesis taught us about the functions of BCR-ABL beyond its kinase activity, and how these functions contribute to CML pathogenesis?Keywords
This publication has 120 references indexed in Scilit:
- BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cellsBiochemical and Biophysical Research Communications, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Does Rap1 deserve a bad Rap?Trends in Biochemical Sciences, 2003
- Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemiaLeukemia, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivityThe Journal of Experimental Medicine, 1999
- Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological dataBritish Journal of Haematology, 1996
- Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populationsCell, 1991
- Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogeneCell, 1991
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988